middle.news
Amgen’s newer medicines gain momentum despite pressure on Prolia and XGEVA
8:05am on Wednesday 4th of November, 2026 AEDT
•
Pharmaceuticals
Read Story
Amgen’s newer medicines gain momentum despite pressure on Prolia and XGEVA
8:05am on Wednesday 4th of November, 2026 AEDT
Key Points
Revenue increased 8% to US$10.4 billion
GAAP diluted EPS rose 19% to US$7.08
Repatha, UPLIZNA and IMDELLTRA posted strong sales growth
Prolia and XGEVA sales fell 45% and 47% respectively
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Amgen (NASDAQ:AMGN)
OPEN ARTICLE